Clinical Development Programme
Clinical trials investigating repotrectinib are currently ongoing in adult and paediatric cancer patients and are exploiting its ability to interfere with NTRK as well as ALK and ROS signaling.
Summary of Ongoing Clinical Trials for Repotrectinib
Registry number |
Name |
Phase |
Title |
NCT03093116 |
TRIDENT-1 |
1/2 |
A study of repotrectinib (TPX-0005) in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements |
NCT04094610 |
- |
1/2 |
A study of repotrectinib in paediatric and young adult subjects harboring ALK, ROS1, OR NTRK1-3 alterations |
NCT05004116 |
- |
1/2 |
A study of repotrectinib in combination with chemotherapy in children and young adults with solid tumour cancer |
NCT05071183 |
- |
1/2 |
A study of repotrectinib in combination with other anticancer therapies for the treatment of subjects with KRAS-mutant solid tumours |
NCT04772235 |
TOTEM |
1 |
Phase I study of repotrectinib and osimertinib in NSCLC patients |
These data are current as of TBC (https://clinicaltrials.gov)